In DLBCL, CD68+CD163+ M2 macrophages are associated with poor clinical outcome (Komohara et al., 2015; Guo et al., 2016) and more frequent extra-nodal involvement (Li Y.-L. This evidence concerns the gene CD68 and diffuse large B-cell lymphoma.